Second generation liposomal cancer therapeutics: Transition from laboratory to clinic

作者：Sen Kacoli; Mandal Mahitosh^*

来源：International Journal of Pharmaceutics, 2013, 448(1): 28-43.

DOI：10.1016/j.ijpharm.2013.03.006

• Liposomes
• Cancer therapeutics
• Drug delivery
• Second generation

Recent innovations and developments in nanotechnology have revolutionized cancer therapeutics. Engineered nanomaterials are the current workhorses in the emerging field of cancer nano-therapeutics. Lipid vesicles bearing anti-tumor drugs have turned out to be a clinically feasible and promising nano-therapeutic approach to treat cancer. Efficient entrapment of therapeutics, biocompatibility, biodegradability, low systemic toxicity, low immunogenicity and ability to bypass multidrug resistance mechanisms has made liposomes a versatile drug/gene delivery system in cancer chemotherapy. The present review attempts to explore the recent key advances in liposomal research and the vast arsenal of liposomal formulations currently being utilized in treatment and diagnosis of cancer.

• 出版日期2013-5-1